Literature DB >> 25845991

Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?

Guru Sonpavde1, Joaquim Bellmunt2.   

Abstract

Entities:  

Keywords:  Advanced urothelial cancer; Salvage therapy

Mesh：

Year:  2015        PMID： 25845991      PMCID： PMC4425398          DOI： 10.1634/theoncologist.2015-0077

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  16 in total

1.  The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Authors:  Richard M Bambury; David J Benjamin; Joshua L Chaim; Emily C Zabor; John Sullivan; Ilana R Garcia-Grossman; Ashley M Regazzi; Irina Ostrovnaya; Aryln Apollo; Han Xiao; Martin H Voss; Gopa Iyer; Dean F Bajorin; Jonathan E Rosenberg
Journal:  Oncologist       Date:  2015-04-06

2.  Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

Authors:  Andrea B Apolo; Irina Ostrovnaya; Susan Halabi; Alexia Iasonos; George K Philips; Jonathan E Rosenberg; Jamie Riches; Eric J Small; Matthew I Milowsky; Dean F Bajorin
Journal:  J Natl Cancer Inst       Date:  2013-02-14       Impact factor: 13.506

Review 3.  Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

Authors:  Guru Sonpavde; Joaquim Bellmunt; Jonathon E Rosenberg; Ashley M Regazzi; Dean F Bajorin; Toni K Choueiri; Angela Q Qu; Guenter Niegisch; Peter Albers; Andrea Necchi; Giuseppe Di Lorenzo; Ronan Fougeray; Yu-Ning Wong; Srikala S Sridhar; Yoo-Joung Ko; Matthew I Milowsky; Matthew D Galsky; Gregory R Pond
Journal:  Clin Genitourin Cancer       Date:  2014-06-10       Impact factor: 2.872

4.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

Authors:  Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

5.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.

Authors:  Yoo-Joung Ko; Christine M Canil; Som D Mukherjee; Eric Winquist; Christine Elser; Andrea Eisen; M Neil Reaume; Liying Zhang; Srikala S Sridhar
Journal:  Lancet Oncol       Date:  2013-05-22       Impact factor: 41.316

Review 7.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Authors:  Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2014-05-29       Impact factor: 13.506

8.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Authors:  Joaquim Bellmunt; Christine Théodore; Tomasz Demkov; Boris Komyakov; Lisa Sengelov; Gedske Daugaard; Armelle Caty; Joan Carles; Agnieszka Jagiello-Gruszfeld; Oleg Karyakin; François-Michel Delgado; Patrick Hurteloup; Eric Winquist; Nassim Morsli; Yacine Salhi; Stéphane Culine; Hans von der Maase
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

9.  Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

Authors:  Neeraj Agarwal; Joaquim Bellmunt; Benjamin L Maughan; Kenneth M Boucher; Toni K Choueiri; Angela Q Qu; Nicholas J Vogelzang; Ronan Fougeray; Guenter Niegisch; Peter Albers; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Srinivas K Tantravahi; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Amitkumar N Mehta; Tomasz M Beer; Cora N Sternberg; Jonathan E Rosenberg; Guru Sonpavde
Journal:  Clin Genitourin Cancer       Date:  2013-09-28       Impact factor: 2.872

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962
View more
  1 in total

1.  Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Authors:  Joaquim Bellmunt; Chensheng Willa Zhou; Stephanie A Mullane; Lillian Werner; Mary-Ellen Taplin; André P Fay; Toni K Choueiri; Anna Orsola; David Y Takeda; William C Hahn; Jaegil Kim; Guru Sonpavde; Michaela Bowden
Journal:  Br J Cancer       Date:  2016-06-23       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.